ASX ANNOUNCEMENT

Lumos Diagnostics Quarterly Activity Statement and Cash Flow Report

Key Highlights from the First Quarter of Financial Year 2026

- **Revenue of US$3.4 million for the quarter,** consistent with the previous corresponding quarter.
- **Q1 Product revenue** of US$1.2 million, up 300% on prior year and **Services revenue** US$2.2 million.
- **Pivotal US$317 / A$487[1] million exclusive distribution agreement for FebriDx® in the U.S. signed with PHASE Scientific**, representing one of the largest distribution agreements by an Australian point-of-care diagnostics company.
- **FebriDx CLIA waiver submission** lodged with FDA in August, demonstrating above target performance, with feedback expected between November 2025 and February 2026.
- **Hologic fFN project continues** with Phase 2, including the additional scope of works in progress.
- **Cash balance of US$4.5 million at 30 September 2025**, up by US$2.5 million over 30 June 2025.
- **Operating cash inflow for Q1 was US$1.8 million** before including US$1.0 million in funds from the exercise of options.
- **Loan facility** for up to US$3.3 million[2] (A$5.0 million) secured from two major shareholders to support working capital needs, if required, through to and beyond the anticipated granting of CLIA waiver.
- **Post reporting date:** U.S. Pediatric study for FebriDx commenced, as announced on 22 October 2025, with first patient tested. The trial is anticipated to run for around 12 months.

All amounts are in USD, the Company's reporting currency, unless otherwise stated.

MELBOURNE, Australia (23 October 2025) – Lumos Diagnostics (ASX: LDX), ("Lumos" or the "Company") a leader in rapid point-of-care diagnostic technologies, is pleased to release its Quarterly Activity Statement and Appendix 4C Quarterly Cash Flow Report for the first quarter of FY26 (Q1 FY26 / the three months ended 30 September 2025).

[1] AUD : USD = 0.651 as at 15 July 2025 [2] AUD : USD = 0.6612

Operational Update

Lumos recorded unaudited revenue of US$3.4 million for the quarter ended 30 September 2025, consistent with revenue in Q1 FY25.

Revenue generated during the quarter from the Services business was US$2.2 million versus US$3.1 million in the previous corresponding period (pcp). Work continued on around 12 projects for customers during the quarter, with the Hologic fFN Development Agreement and the Intellectual Property licensing revenue associated with the Hologic IP Agreement continuing to generate the majority of the revenue. The decline on the pcp was primarily due to the reduced monthly revenue recognition of the Intellectual Property Agreement (US$10.0 million upfront payment), from US$0.5 million to US$0.16 million per month, as a result of the extension of the project timeline.

Revenue from the Products business during the quarter was US$1.2 million, versus US$0.3 million in Q1 FY25, an increase of 300%, which includes the US$1.0 million exclusivity fee received from PHASE Scientific in July 2025. Increasing adoption of FebriDx® across the U.S. resulted in five-fold revenue growth on the pcp for this product. The sales team continues to seek revenue from the third-party supplied CorDx Flu A/B/COVID combo test as a replacement for Lumos' proprietary ViraDx® test, which was no longer price competitive.

Development Services and Contract Manufacturing

Lumos generates revenue from the provision of point of care diagnostic test and custom reader development services, contract manufacturing and IP license revenue. Development services included ongoing work on several projects during the quarter, with projects for Hologic, Burnet Diagnostics Initiative, Huvepharma, TeleMedVet and more recently Aptatek Biosciences continuing during the period.

Hologic -fFN Diagnostic Product

On 11 January 2024, Lumos announced an IP licensing agreement (worth US$10.0 million, with payment received in FY24) and a Development Agreement (initially worth US$4.7 million) with Hologic, a leading global women's health provider, to develop the next generation of Hologic's on-market fFN diagnostic product for pre-term birth, for which Hologic is the only global manufacturer. A key focus of the development program is to adapt the test for use on the Lumos proprietary reader platform and provide improved connectivity options.

The development project has since been expanded by two additional scope of works (SOW), one in March 2025 for between US$0.6 – US$0.8 million (relating to the delivery of the system prototype in Phase 3) and the other in August 2025 for between US$0.7 - US$0.9 million (relating to the assay feasibility work in Phase 2).

In addition, the payment schedule for the project, as allocated across the three phases, was recently amended. This new payment schedule is outlined below.

Including the two additional SOW's, the body of work under the Development Agreement is being conducted across three phases (which include nine milestones), providing total milestone payments of between US$6.0 - US$6.4 million, structured as follows:

- Phase 1 (milestone 1) - Product Definition and Planning: define the parameters for the product and establish a project plan - US$0.4 million – this phase has been completed, and payment has been received;
- Phase 2 (milestones 2 and 3) - Assay Feasibility: conduct work to demonstrate the assay can detect the biomarkers - US$2.5 to US$2.7 million – work on the first milestone of this phase has been completed. Work on the second and final milestone for this phase, including the additional SOW is nearing completion. For this phase, payments of US$1.8 million have been received so far (with US$1.3 million of this received in October 2025).
- Phase 3 (milestones 4 to 9) - System Prototype Delivery: deliver a working prototype of the system – US$3.1 to US$3.3 million – milestone 4 and 5 of this phase are in progress, including the additional hardware system prototype SOW. Whilst Lumos completes the additional SOW on assay feasibility, work on these phase 3 milestones is likely to be delayed, extending the project timeline. For this phase, payments of US$1.0 million have been received so far.

Aptatek Biosciences – PheCheck in-home monitoring for PKU

On 1 September 2025, Lumos secured a follow-on development contract with New Jersey-based Aptatek Biosciences. (Aptatek) to advance the PheCheck™ aptamer-based, in-home monitoring tool for the screening and management of phenylketonuria (PKU).

Under the new contract, Lumos will focus on maturing the design of the tests, blood processing unit, and readers; conducting formal verification testing to ensure the device meets product requirements for clinical trials and U.S. Food and Drug Administration (FDA) submission.

The contract, valued at approximately US$1.5 million and charged on a time-and-materials basis, has commenced and will run for around 10 months. Additional revenue opportunities are anticipated through Lumos' support of clinical trials and ongoing instrument manufacturing in subsequent phases of the partnership.

Products Division

We provide a summary of the following product updates below.

FebriDx®

FebriDx® is Lumos' unique, rapid point of care test that helps clinicians differentiate between bacterial and non-bacterial acute respiratory infections through a simple fingerstick blood sample in around 10 minutes. To date, Lumos has received regulatory registrations for the use of FebriDx® in the U.S., UK, Europe, Canada, UAE and Australia. During the quarter, FebriDx® achieved a number of pivotal milestones.

PHASE Scientific exclusive distribution agreement: On 16 July 2025, Lumos entered into one of the largest distribution agreements signed by an Australian point-of-care diagnostics company. The six-year agreement provides PHASE Scientific with exclusive U.S. distribution rights for FebriDx® and is valued at US$317/ A$487 million. Upon execution, a US$1.0 million distribution and exclusivity fee (now paid) and a US$1.0 million pre-paid purchase order payment (now paid), were required. A further US$1.5 million pre-paid purchase order was received following the FebriDx® CLIA waiver application submission to the FDA. An additional US$5.0 million, non-refundable, prepaid purchase order commitment will be payable upon the anticipated granting of CLIA waiver.

Further details are available in the ASX release dated 16 July 2025. A webinar was held on 16 July 2025 where members of the Lumos team discussed the partnership in more detail, together with Bob Gergen, VP of Commercial Operations for PHASE Scientific. A recorded copy of the webinar is available for viewing, here.

CLIA waiver study completion and submission: On 18 August 2025, Lumos announced the completion of the clinical study and submission of its application to the FDA for CLIA waiver classification for FebriDx®. The clinical study demonstrated a 99.1% concordance between trained and untrained operators testing bacterial positive patients, and a 98.4% concordance for non-bacterial patients. Lumos planned and executed the clinical study to demonstrate the simplicity and ease of use of the FebriDx® device and to demonstrate that FebriDx® poses insignificant risk of erroneous results in the hands of untrained users – the key metric required to achieve CLIA waived categorization. Lumos expects to receive feedback from the FDA between November 2025 and February 2026.

Completion and submission of the study triggered milestones payments of US$1,253,520 from BARDA, which were received during the quarter. The one remaining milestone payment from BARDA, of US$507,377 will be receivable upon the successful grant of CLIA waiver by the FDA.

Partnership with PRO-spectus: In August 2025, Lumos entered into a partnering agreement with US-based market access consultancy, PRO-spectus, to support the marketing, market access, and reimbursement of its flagship point-of-care test, FebriDx®. The program will initially run through to December 2026.

With reimbursement for FebriDx® now available through US Medicare, Lumos will focus on securing coverage from US private insurance payors to further broaden patient access. Private payors account for approximately 60% of the US health insurance market, covering more than 170 million Americans, with a small number of large insurers controlling nearly half the market. At the same time, the private payor market also includes hundreds of smaller insurers, which, while collectively important, are more difficult to reach and require a targeted approach. By addressing both the large and smaller players, Lumos aims to ensure more healthcare providers and patients can benefit from access to FebriDx®. Further information is available from the ASX release dated 14 August 2025.

CLIA waived paediatric study commences: On 1 September 2025, BARDA exercised its option to support Lumos in conducting a clinical study and regulatory submission aimed at expanding the age eligibility for FebriDx® use to include 2 to 12 years in CLIA waived settings ("paediatric study"). The study will be conducted across approximately 20 clinical sites in the US. The study is expected to run for around 12 months, following which a formal submission will be prepared for the FDA.

Milestone payments from BARDA to Lumos of US$6.2 million will be triggered upon the achievement of twelve milestone events, including clinical trial set-up, patient recruitment, FDA application submission, and FDA granting of 510(k) clearance and CLIA waiver categorization for children 2 – 12 years of age. To date, US$0.4 million has been received from BARDA.

On 22 October 2025, Lumos announced that the study has commenced with first patient tested and contracts for around 14 of a proposed 20 clinical sites signed so far.

Second ANZ Distribution Agreement for FebriDx®: In September 2025, Lumos signed a second distribution agreement for its flagship test, FebriDx®, in Australia and New Zealand. The new partnership with healthcare distributor Amtech (part of YesGroup) complements Lumos' existing agreement with Henry Schein. Amtech's reach and long-standing presence in the local healthcare market, alongside the existing Henry Schein agreement positions FebriDx® to be more widely accessible to clinicians.

Women's Sexual Health Product Development

Progress continues on identifying and developing a pipeline of future women's sexual health point-of-care diagnostic tests. The company is exploring potential products aimed at addressing key unmet needs in this important and growing healthcare segment. These initiatives form part of Lumos' broader commitment to improving access, convenience, and early detection through innovative diagnostic solutions designed specifically for women.

Of the potential products, three have now advanced to the technical feasibility stage. These early milestones are encouraging and reflect the Company's disciplined and evidence-based approach to innovation. Lumos is targeting the transition of at least one of these products into formal product development within the next 6 - 8 months, as the Company continues to build a robust pipeline focused on delivering impactful solutions in women's health.

Loan Facility of US$3.3 million / A$5.0 million Secured with Major Shareholders

On 17 July 2025, Lumos entered into a binding conditional term sheet for a secured US$3.3 million / A$5.0 million loan facility with major supportive shareholders Tenmile and Ryder Capital, with the definitive agreements executed on 9 September 2025. The facility provides funding of up to A$5.0 million over a 12-month term, with an option to extend for a further 12 months.

The loan facility is designed to provide access to working capital, if needed, through and beyond the anticipated granting of the CLIA waiver for FebriDx®, while minimising shareholder dilution.

As part of the agreement, Tenmile and Ryder Capital each received 7.5 million Lumos shares in satisfaction of establishment and service fees. The Company has also terminated its previous convertible note arrangement, including the unused second tranche of A$4.0 million with Lind Global Fund II and SBC Global Investment Fund.

Summary of Cash Receipts and Outflows

The net operating cash inflow for Q1 FY26 was US$1.8 million, a significant improvement from the US$2.6 million cash outflow in the pcp.

Lumos generated cash receipts from customers of US$5.3 million for the first quarter ended 30 September 2025, compared to US$1.2 million receipts from customers in the pcp.

Cash operating expenses for Q1 FY26 were US$5.3 million, an increase of US$1.7 million over Q1 FY25 expenses of $3.6 million. These operating expenses were in line with expectations and requirements to run product trials and meet project delivery expectations for customers. This increase over the pcp was primarily due to FebriDx trial costs of around US$1.0 million and additional project delivery costs during the quarter.

During the quarter cash receipts of US$1.9 million were received from government grants and tax incentives, with the majority of this relating to payments from BARDA for the CLIA waiver trial of US$1.5 million and the Paediatric trial of US$0.4 million.

As in prior quarters, there was essentially no capital expenditure during Q1 FY26.

After including investing activities and lease payment expenses, net cash inflow for the quarter totaled US$1.5 million.

A further US$1.0 million (A$1.4 million) was received during the period from the exercise of 20.8 million options at A$0.0707 each by SBC Global Investment Fund.

Including this receipt, the total net cash inflow for the quarter was US$2.5 million, bringing the cash balance at the end of the quarter, Q1 FY26, to US$4.5 million.

Payments to Related Entities

In accordance with Listing Rule 4.7C.3 and as outlined in Section 6.1 of Appendix 4C, the Company discloses payments to related entities of US$288,000, comprising directors' fees and superannuation for Sam Lanyon, Catherine Robson, Bronwyn Le Grice and Larry Mehren, consulting fees for Sam Lanyon, and salary, bonus, medical insurance and 401K retirement payments for Doug Ward.

The consulting fees for Sam Lanyon are related to his advisory services in relation to investor relations, capital raising and commercialisation activities (ASX: 28 September 2023). Mr Lanyon receives A$80,000 per annum, inclusive of superannuation, for these services.

Key Priorities

The key focus areas for Lumos are currently summarized as follows:

- FDA decision on the CLIA waiver application for FebriDx® is expected between November 2025 and February 2026.
- Implement the agreement with PHASE Scientific, drive reimbursement coverage, and plan for volume scale-up.

- Progress the BARDA paediatric study – to address an important clinical market for the 2-12 age group and expand the U.S. market for FebriDx® by approx. 15% - 20%.
- Deliver on the Hologic fFN development milestones - milestone 3 assay feasibility work from Phase 2 & the Phase 3 milestones 4 – 9.
- Progress to formal product development for the first Lumos branded women's health diagnostics test.

In closing, CEO Doug Ward said: *"I am very encouraged with the progress Lumos has achieved during the quarter across our product, services and corporate initiatives. The completion and submission of the CLIA waiver application for FebriDx®, the execution of our exclusive U.S. distribution agreement with PHASE Scientific, and the commencement of the BARDA-supported paediatric study all mark important milestones in advancing our strategy.*

Lumos maintains a sound balance sheet with financial flexibility, supported by milestone receipts from BARDA, Hologic, payments under the PHASE Scientific agreement, and the flexible loan facility secured from major shareholders Tenmile and Ryder Capital. These initiatives position Lumos well as we await feedback from the FDA on our FebriDx® CLIA waiver submission.

Overall, I am very pleased with the momentum we are building and confident in Lumos' ability to execute on our strategy to deliver innovative, accessible diagnostic test solutions globally.

"Looking ahead, we remain firmly focused on our strategic priorities and committed to building a strong, sustainable business that delivers long-term value for patients, partners, and shareholders alike."

Annual General Meeting Invitation

The Company invites investors and analysts to attend the Annual General Meeting to be held online on Friday, 24 October 2025 at 9:30am (AEDT).

Participants can pre-register ahead of time via the following link:

https://vistra.zoom.us/webinar/register/WN_JMJFQFmxRVm6p2UEqAE0Vw

Once the registration form is completed, investors will receive a confirmation email with details on how to access the meeting. The Lumos team looks forward to welcoming those shareholders and potential investors who are able to attend.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:
Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 423 139 163

Investor Contact:
George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:
Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
info@lumosdiagnostics.com
+61 3 9087 1598

Appendix 4C

Quarterly Cash Flow report for entities subject to Listing Rule 4.7B

Name of entity

Lumos Diagnostics Holding Limited

ABN	**Quarter ended ("current quarter")**
66 630 476 970	30 September 2025

Consolidated statement of cash flows		**Current quarter US$'000**	**Year to date (3 months) US$'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	5,314	5,314
1.2	Payments for		
	(a) service delivery, research and development	(1,003)	(1,003)
	(b) product manufacturing and operating costs	(698)	(698)
	(c) sales, advertising and marketing	(305)	(305)
	(d) medical affairs and clinical trial costs	(969)	(969)
	(e) leased assets	-	-
	(f) staff costs*	(1,695)	(1,695)
	(g) administration and corporate costs	(669)	(669)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	5	5
1.5	Interest and other costs of finance paid	(134)	(134)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	1,952	1,952
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**1,798**	**1,798**

*Staff costs have been allocated to their respective departments above.

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(9)	(9)
	(d) investments	-	-

Consolidated statement of cash flows		Current quarter US$'000	Year to date (3 months) US$'000
	(e) intellectual property	-	-
	(f) other non-current assets (including capitalised product development costs)	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(9)**	**(9)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	968	968
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other:		
	Lease payments (principal component)	(254)	(254)
3.10	**Net cash from / (used in) financing activities**	**714**	**714**

Consolidated statement of cash flows		Current quarter US$'000	Year to date (3 months) US$'000
4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	1,956	1,956
4.2	Net cash from / (used in) operating activities (item 1.9 above)	1,798	1,798
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(9)	(9)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	714	714
4.5	Effect of movement in exchange rates on cash held	29	29
4.6	**Cash and cash equivalents at end of period**	**4,488**	**4,488**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter US$'000	Previous quarter US$'000
5.1	Bank balances	4,488	1,956
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**4,488**	**1,956**

6.	Payments to related parties of the entity and their associates	Current quarter US$'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	288
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end US$'000**	**Amount drawn at quarter end US$'000**
7.1	Loan facilities	3,306	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	3,306	-

7.5	**Unused financing facilities available at quarter end**	3,306

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Item 7.1 includes a loan facility of A$5.0 million announced on 17 July 2025.

The company completed the formal documentation for the loan facility on 9 September 2025 with major shareholders Tenmile Ventures Pty Ltd and Ryder Capital Management Pty Ltd.

The interest rate on drawn amounts is 15.0% per annum.

Maturity date is 12 months from the first drawdown date, with options to extend for a further 12 months.

Drawdowns are at the discretion of the Company.

The amount shown above is for the full loan facility of A$5.0 million at an FX rate of A$1.00:US$0.6612.

Refer to the ASX announcements for further details on this loan facility.

8.	**Estimated cash available for future operating activities**	**US$'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	1,798
8.2	Cash and cash equivalents at quarter end (item 4.6)	4,488
8.3	Unused finance facilities available at quarter end (item 7.5)	3,306
8.4	Total available funding (item 8.2 + item 8.3)	7,794
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	N/A

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: **23 October 2025**

Authorised by: **The Lumos Disclosure Committee**
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.